Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Inmune Bio Inc
(NQ:
INMB
)
8.820
+0.390 (+4.63%)
Streaming Delayed Price
Updated: 3:08 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
75,617
Open
8.460
Bid (Size)
8.800 (2)
Ask (Size)
8.900 (3)
Prev. Close
8.430
Today's Range
8.380 - 8.850
52wk Range
6.500 - 14.74
Shares Outstanding
17,703,692
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
April 08, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q4 2023
March 28, 2024
INMB stock results show that INmune Bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
-21.39%
-21.39%
1 Month
-19.96%
-19.96%
3 Month
-22.29%
-22.29%
6 Month
+18.71%
+18.71%
1 Year
+8.89%
+8.89%
More News
Read More
INmune Bio: Q4 Earnings Insights
March 28, 2024
Via
Benzinga
A Preview Of INmune Bio's Earnings
March 27, 2024
Via
Benzinga
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
March 26, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
March 13, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 28, 2024
March 28, 2024
Via
Benzinga
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
March 05, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 12, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
February 06, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
January 30, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
Why Is Elevai Labs (ELAB) Stock Up Today?
January 16, 2024
Via
InvestorPlace
Why Elevai Labs Stock Is Trading Higher
January 16, 2024
Via
Benzinga
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
January 16, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
January 02, 2024
From
INmune Bio, Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
December 19, 2023
Via
InvestorPlace
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
December 18, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
November 29, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
November 27, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
November 17, 2023
Via
Investor's Business Daily
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
November 15, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
October 31, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
October 30, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 17, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1
October 16, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.